Follistatin as potential therapeutic target in prostate cancer

Targeted Oncology

Volumn 8, Issue 4, 2013, Pages 215-223

  Sepporta, Maria Vittoria ^a   Tumminello, Francesca Maria ^a   Flandina, Carla ^a   Crescimanno, Marilena ^a   Giammanco, Marco ^a   La Guardia, Maurizio ^a   Di Majo, Danila ^a   Leto, Gaetano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Activin; Bone metastasis; Cancer; Follistatin; Prostate cancer

Indexed keywords

ACT PROTEIN; FOLLISTATIN; TUMOR MARKER; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER GROWTH; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; TUMOR VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; FOLLISTATIN; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS;

EID: 84890553027     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0268-7     Document Type: Review

References (97)

1. Carson CC 3rd (2006) Carcinoma of the prostate: overview of the most common malignancy in men. N C Med J 67(2):122-127
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581-592
3. Simmons MN, Stephenson AJ, Klein EA (2007) Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51:1175-1184
4. Gioeli D (2005) Signal transduction in prostate cancer progression. Clin Sci 108:293-308
5. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocrine Rev 22(6):836-858
6. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF (2001) The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 180(1-2):149-153
7. Gold E, Risbridger G (2012) Activins and activin antagonists in the prostate and prostate cancer. Mol Cell Endocrinol 359(1-2):107-112
8. Phillips DJ, de Kretser DM (1998) Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19(4):287-322
9. Welt C, Sidis Y, Keutmann H, Schneyer A (2002) Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med 227:724-752
10. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K, Sugino H (1993) Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 68:15579-15587
11. Inouye S, Ling N, Shimasaki S (1992) Localization of the heparin-binding site of follistatin. Mol Cell Endocrinol 90:1-6
12. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A (1995) Multiple defects and perinatal death in mice deficient in follistatin. Nature 374(6520):360-363
13. Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, Corbo L, Magaud JP, Rimokh R (2002) Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene 21(14):2227-2235
14. Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM (2009) FoxL2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem 284(12):7631-7645
15. Winters SJ, Ghooray D, Fujii Y, Moore JP Jr, Nevitt JR, Kakar SS (2007) Transcriptional regulation of follistatin expression by GnRH in mouse gonadotroph cell lines: evidence for a role for cAMP signaling. Mol Cell Endocrinol 271(1-2):45-54
16. Eichberger T, Kaser A, Pixner C, Schmid C, Klingler S, Winklmayr M, Hauser-Kronberger C, Aberger F, Frischauf AM (2008) GLI2-specific transcriptional activation of the bone morphogenetic protein/activin antagonist follistatin in human epidermal cells. Biol Chem 283(18):12426-12437
17. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T (2009) BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379(2):261-266
18. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R (2009) Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology 150(3):1259-1268
19. Willert J, Epping M, Pollack JR, Brown PO, Nusse R (2002) A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2:2-8
20. Yao HH, Matzuk MM, Jorgez CJ, Menke DB, Page DC, Swain A, Capel B (2004) Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 230(2):210-215
21. Necela BM, Su W, Thompson EA (2008) Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. Biol Chem 283(44):29784-29794
22. Garcia LA, King KK, Ferrini MG, Norris KC, Artaza JN (2011) 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 152(8):2976-2986
23. Ruspita I, Miyoshi K, Muto T, Abe K, Horiguchi T, Noma T (2008) Sp6 downregulation of follistatin gene expression in ameloblasts. J Med Invest 55(1-2):87-98
24. Schneyer AL, Wang Q, Sidis Y, Sluss PM (2004) Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab 89(10):5067-5075
25. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS (2005) The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9(4):535-543
26. Michel U, Albiston A, Findlay JK (1990) Rat follistatin: gonadal and extragonadal expression and evidence for alternative splicing. Biochem Biophys Res Commun 173(1):401-407
27. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF Jr (1996) Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 137(1):240-247
28. Hashimoto O, Kawasaki N, Tsuchida K, Shimasaki S, Hayakawa T, Sugino H (2000) Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin. Cell Signal 12(8):565-571
29. Sugino H, Sugino K, Hashimoto O, Shoji H, Nakamura T (1997) Follistatin and its role as an activin-binding protein. J Med Invest 44(1-2):1-14
30. Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M (2006) Structural basis for the inhibition of activin signalling by follistatin. EMBO J 25:1035-1045
31. Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS (2007) Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem 282(21):15930-15939
32. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A (2006) Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147(7):3586-3597
33. Innis CA, Hyvönen M (2003) Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding. J Biol Chem 278(41):39969-39977
34. McConnell DS, Wang Q, Sluss PM, Bolf N, Khoury RH, Schneyer AL, Midgley AR Jr, Reame NE, Crowley WF Jr, Padmanabhan V (1998) A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab 83(3):851-858
35. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N (1998) Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 95(16):9337-9342
36. Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E, Patel K (2002) Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol 243(1):115-127
37. Glister C, Kemp CF, Knight PG (2004) Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 127(2):239-254
38. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K (2004) Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270(1):19-30
39. Nogai H, Rosowski M, Grün J, Rietz A, Debus N, Schmidt G, Lauster C, Janitz M, Vortkamp A, Lauster R (2008) Follistatin antagonizes transforming growth factor-beta3-induced epithelial-mesenchymal transition in vitro: implications for murine palatal development supported by microarray analysis. Differentiation 76(4):404-416
40. Phillips DJ, McFarlane JR, Hearn MT, de Kretser DM (1997) Inhibin, activin and follistatin bind preferentially to the transformed species of alpha 2-macroglobulin. J Endocrinol 155(1):65-71
41. Gao X, Hu H, Zhu J, Xu ZI (2007) Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett 581(28):5505-5510
42. Wang Q, Tabatabaei S, Planz B et al (1999) Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. J Urol 161(4):1378-1384
43. Anderson RA, Evans LW, Irvine DS, McIntyre MA, Groome NP, Riley SC (1998) Follistatin and activin A production by the male reproductive tract. Hum Reprod 13(12):3319-3322
44. Winnall WR, Wu H, Sarraj MA, Rogers PAW, de Kretser DM, Girling JE, Hedger M (2012) Expression patterns of activin, inhibin and follistatin variants in the adult male mouse reproductive tract suggest important roles in the epididymis and vas deferens. Reproduction, Fertility and Development doi: 10.1071/RD11287
45. Thomas TZ, Chapman SM, Hong W et al (1998) Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 34(1):34-43
46. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92(4):221-236
47. Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, Risbridger GP (2001) Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 237(1):145-158
48. Prins GS, Putz O (2008) Molecular signaling pathways that regulate prostate gland development. Differentiation 76(6):641-659
49. Cunha GR, Hayward SW, Wang YZ (2002) Role of stroma in carcinogenesis of the prostate. Differentiation 60:473-485
50. Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS (2009) Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res 69(5):1739-1747
51. Wong YC, Tam NN (2002) Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 70:633-645
52. Vaarala MH, Porvari K, Kyllönen A, Vihko P (2000) Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 80(8):1259-1268
53. Härkönen P, Törn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, Isomaa V, Vihko P (2003) Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 88(2):705-712
54. van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, de Jong FH (2000) Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 82(1):112-117
55. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, Risbridger GP (1999) Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140:5303-5309
56. Handayani R, Rice L, Cui Y, Medrano TA, Samedi VG, Baker HV, Szabo NJ, Shiverick KT (2006) Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr 136(1):75-82
57. van der Poel HG, Hanrahan C, Zhong H, Simons JW (2003) Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30(6):380-386
58. Havard M, Dautry F, Tchénio T (2011) A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. J Biol Chem 286(51):44177-44186
59. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG (2007) Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 178(3 Pt 1):1086-1091
60. Gao X, Wei S, Lai K, Sheng J, Su J, Zhu J, Dong H, Hu H, Xu Z (2010) Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis. J Biol Chem 285(47):36857-368564
61. Lyssiotis CA, Vander-Heiden MG, Muñoz-Pinedo C, Emerling BM (2012) Emerging concepts: linking hypoxic signaling and cancer metabolism. Cell Death Dis 3:329. doi: 10.1038/cddis.2012.75
62. Li S, Ibaragi S, Hu GF (2011) Angiogenin as a molecular target for the treatment of prostate cancer. Curr Cancer Ther Rev 7(2):83-90
63. Yoshioka N, Wang L, Kishimoto K et al (2006) A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103(39):14519-14524
64. Tsuji T, Sun Y, Kishimoto K et al (2005) Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res 65(4):1352-1360
65. Ajiboye S, Sissung TM, Sharifi N, Figg WD (2010) More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. BJU Int 105(7):913-916
66. Kozian DH, Ziche M, Augustin HG (1997) The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest 76(2):267-270
67. Glienke J, Schmitt AO, Pilarsky C, Hinzmann B, Weiss B, Rosenthal A, Thierauch KHD (2000) Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem 267(9):2820-2830
68. Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin (Shanghai) 40(7):619-624
69. Oh IS, Kim GH (2004) Vascular endothelial growth factor upregulates follistatin in human umbilical vein endothelial cells. Biotechnol Bioprocess Eng 9:201-206
70. Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825(1):29-36
71. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI, Werb Z (2010) Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 70:2224-2234
72. Krneta J, Kroll J, Alves F, Prahst C, Sananbenesi F, Dullin C, Kimmina S, Phillips DJ, Augustin HG (2008) Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 66:5686-5695
73. Li WW, Li VW, Hutnik M, Chiou AS (2012) Tumor angiogenesis as a target for dietary cancer prevention. J Oncol. doi: 10.1155/2012/879623
74. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 14:660-667
75. Seder CW, Hartojo W, Lin L et al (2009) Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia 11(4):388-396
76. Chlenski A, Liu S, Baker LJ et al (2004) Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res 64(20):7420-7425
77. Sakamoto H, Kimura H, Sekijima M, Matsumoto K, Arao T, Chikugo T, Yamada Y, Kitano M, Ito A, Takeyama Y, Kudo M, Nishio K (2012) Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Jpn J Clin Oncol 42(2):105-112
78. Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K (2011) Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 26(11):1604-1611
79. Hofland J, van Weerden WM, Steenbergen J, Dits NF, Jenster G, de Jong FH (2012) Activin A stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology 153(12):5726-5734
80. Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, Schulte-Hermann R (2002) Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 35(1):1-5
81. Stove C, Vanrobaeys F, Van Devreese B, Beeumen J, Mareel M, Bracke M (2004) Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. Oncogene 23(31):5330-5339
82. Grusch M, Drucker C, Peter-Vörösmarty B, Erlach N, Lackner A, Losert A, Macheiner D, Schneider WJ, Hermann M, Groome NP, Parzefall W, Berger W, Grasl-Kraupp B, Schulte-Hermann R (2006) Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45(5):673-680
83. Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549
84. Sardana G, Jung K, Stephan C, Diamandis EP (2008) Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 7(8):3329-3338
85. Tumminello FM, Badalamenti G, Fulfaro F, Incorvaia L, Crescimanno M, Flandina C, Sepporta MV, Leto G (2010) Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis 27(8):549-555
86. Kawabata N, Kamiya N, Suzuki N, Matsumoto M, Takagi M (2007) Changes in extracellular activin A: follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes. Life Sci 81(1):8-18
87. Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG, van der Spek PJ, Visser JA, de Jong FH, Pols HA, van Leeuwen JP (2007) The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 21(11):2949-2960
88. Gajos-Michniewicz A, Piastowska AW, Russell JA, Ochedalski T (2010) Follistatin as a potent regulator of bone metabolism. Biomarkers 15(7):563-574
89. Gajos-Michniewicz A, Pawlowska E, Ochedalski T, Piastowska-Ciesielska A (2012) The influence of follistatin on mechanical properties of bone tissue in growing mice with overexpression of follistatin. J Bone Miner Metab 30(4):426-433
90. Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA (2006) Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 244(2):274-288
91. Chen M, Sinha M, Luxon BA, Bresnick AR, O'Connor KL (2009) Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 284(3):1484-1494
92. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR (2005) Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20(12):2189-2199
93. Buijs JT, Petersen M, van der Horst G, van der Pluijm G (2010) Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des 16(11):1291-1300
94. Simon DP, Vadakkadath Meethal S, Wilson AC, Gallego MJ, Weinecke SL, Bruce E, Lyons PF, Haasl RJ, Bowen RL, Atwood CS (2009) Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia 11(4):365-376
95. Najy AJ, Day KC, Day ML (2008) ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 68(4):1092-1099
96. Li D, Chiu H, Gupta V, Chan DW (2012) Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta 413(19-20):1506-1511
97. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G (2006) Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23(2):117-212